Real-life costs and effects of an implementation program to increase thrombolysis in stroke

Neurology

Volumn 79, Issue 6, 2012, Pages 508-514

  Dirks, Maaike ^a   Baeten, Stefan A ^b   Dippel, Diederik W J ^a   Van Exel, N Job A ^b   Van Wijngaarden, Jeroen D H ^b   Huijsman, Robbert ^b   Koudstaal, Peter J ^a   Niessen, Louis W ^c,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 84866139107     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31826356bf     Document Type: Article

References (25)

1. Kolominsky-Rabas PL, Heuschmann PU, Marschall D, et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke 2006;37:1179-1183.
2. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke 1996;27:1459 -1466.
3. Fagan SC, Morgenstern LB, Petitta A, et al. Costeffectiveness of tissue plasminogen activator for acute ischemic stroke: NINDS rt-PA Stroke Study Group. Neurology 1998;50:883-890.
4. Sinclair SE, Frighetto L, Loewen PS, et al. Cost-utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics 2001;19:927-936.
5. Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou- Chebl A, Nadzam DM. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004;61:346 -350.
6. Schouten LM, Hulscher ME, van Everdingen JJ, Huijsman R, Grol RP. Evidence for the impact of quality improvement collaboratives: systematic review. BMJ 2008; 336:1491-1494.
7. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings: The Cochrane Effective Practice and Organization of Care Review Group. BMJ 1998;317:465-468.
8. Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004; 8:iii-72.
9. Dirks M, Niessen LW, van Wijngaarden JD, et al. Promoting thrombolysis in acute ischemic stroke. Stroke 2011;42:1325-1330.
10. Gandjour A, Lauterbach KW. How much does it cost to change the behavior of health professionals? A mathematical model and an application to academic detailing. Med Decis Making 2005;25:341-347.
11. Berwick DM. Crossing the boundary: changing mental models in the service of improvement. Int J Qual Health Care 1998;10:435-441.
12. Campbell MK, Elbourne DR, Altman DG. CONSORT statement: extension to cluster randomised trials. BMJ 2004;328:702-708.
13. Post PN, Stiggelbout AM, Wakker PP. The utility of health states after stroke: a systematic review of the literature. Stroke 2001;32:1425-1429.
14. The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199 -208.
15. Lamers LM, Stalmeier PF, McDonnell J, Krabbe PF, van Busschbach JJ. Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff [in Dutch]. Ned Tijdschr Geneeskd 2005;149:1574 -1578.
16. Niessen LW, Barendregt JJ, Bonneux L, Koudstaal PJ. Stroke trends in an aging population: The Technology Assessment Methods Project Team. Stroke 1993;24:931-939.
17. Baeten SA, van Exel NJ, Dirks M, Koopmanschap MA, Dippel DW, Niessen LW. Lifetime health effects and medical costs of integrated stroke services: a nonrandomized controlled cluster-trial based life table approach. Cost Eff Resour Alloc 2010;8:21.
18. van Exel NJ, Koopmanschap MA, Scholte Op Reimer WJ, Niessen LW, Huijsman R. Cost-effectiveness of integrated stroke services. QJM 2005;98:415-425.
19. Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. Guidelines for pharmacoeconomic studies: recommendations from the panel on cost effectiveness in health and medicine: Panel on Cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997;11:159-168.
20. The Netherlands Society of Neurology, Dutch Institute for Healthcare Improvement CBO. Stroke Guideline: Diagnosis, Treatment and Care [in Dutch]. The Netherlands Society of Neurology, Dutch Institute for Healthcare Improvement CBO: 2008.
21. Ehlers L, Andersen G, Clausen LB, Bech M, Kjolby M. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke 2007;38:85-89.
22. Sandercock P, Berge E, Dennis M, et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 2004;35:1490 -1497.
23. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FHH. Guideline for cost studies: methods and standardised resource prices for economic evaluations in health care [in Dutch]. College of Health Insurances; 2004. Available at: http://www.ispor.org/peguidelines/source/ Methodenenstandaardkostprijzenvooreconomischeevaluatiesindegezondheidszorg.pdf. Accessed July 2, 2012.
24. Schwamm LH, Fonarow GC, Reeves MJ, et al. Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation 2009;119:107-115.
25. Soumerai SB, McLaughlin TJ, Gurwitz JH, et al. Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial. JAMA 1998;279:1358 -1363.